Multidisciplinary Approach to Antiplatelet Management in Coronary Syndromes
Updated: October 13, 2026
- Antiplatelet therapy is foundational for acute coronary syndromes (ACS) and chronic coronary disease (CCD), but medication selection, dose, and duration should be individualized by thrombotic and bleeding risk.
- Guideline-based therapy remains the foundation of antiplatelet management, with dual antiplatelet therapy (DAPT) duration and P2Y12 inhibitor selection tailored to the clinical scenario.
- Shorter DAPT strategies may reduce bleeding in selected patients, but limitations of existing evidence warrant caution when applying these approaches to patients at high thrombotic risk.